☆ 4.6 Article

A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma

ORAL ONCOLOGY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Cancer statistics, 2022

Rebecca L. Siegel et al.

Summary: Each year, the American Cancer Society compiles data on cancer occurrence and outcomes in the United States. The latest data shows that breast and prostate cancer progress has stagnated, while lung cancer has shown improvements in survival rates. Lung cancer incidence for advanced disease has declined while localized-stage rates have increased, resulting in higher survival rates. Mortality patterns align with incidence trends, with lung cancer deaths declining rapidly, breast cancer deaths slowing, and prostate cancer deaths stabilizing.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

添加到收藏夹

Article Oncology

Palbociclib Renders Human Papilloma Virus-Negative Head and Neck Squamous Cell Carcinoma Vulnerable to the Senolytic Agent Navitoclax

Nicholas J. Gadsden et al.

Summary: Inhibition of CDK4/6 leads to senescence in HPV- HNSCC, which can be effectively eliminated by combining palbociclib and navitoclax. This combination therapy decreases cell survival and increases apoptosis levels in HPV- HNSCC cell lines.

MOLECULAR CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Article Oncology

Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial

Assuntina G. Sacco et al.

Summary: The study aimed to evaluate the anti-tumour activity of PD-1 blockade with EGFR inhibition in recurrent or metastatic head and neck squamous cell carcinoma. Results showed a 45% overall response rate at 6 months for the combination of pembrolizumab and cetuximab.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-na?ve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial

Douglas R. Adkins et al.

Summary: The study examined whether palbociclib and cetuximab prolonged overall survival compared to placebo and cetuximab. The results showed that there was no significant difference in median overall survival between the two groups, with median OS of 9.7 months and 7.8 months in the palbociclib group and placebo group respectively.

ORAL ONCOLOGY (2021)

添加到收藏夹

Article Cell Biology

Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors

Roman Uzhachenko et al.

Summary: Inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6i) delay metastatic breast cancer progression, while also enhancing the efficacy of T cell-based therapies by inducing chemokines that recruit activated CD8(+) T cells to the tumor. The metabolic stress induced by CDK4/6i treatment in breast cancer cells plays a key role in this process, suggesting a link between tumor metabolic vulnerabilities and anti-tumor immunity.

CELL REPORTS (2021)

添加到收藏夹

Article Oncology

Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer

Yuan Yuan et al.

Summary: This phase I/II trial investigated the safety and efficacy of palbociclib, pembrolizumab, and letrozole in HR+ HER2(-) metastatic breast cancer patients. The combination therapy showed good tolerability and a complete response rate of 31%. Confirmatory trials are needed to better understand the immune-priming effects of CDK4/6 inhibitors.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Article Oncology

Genomic Characterization and Therapeutic Targeting of HPV Undetected Cervical Carcinomas

Fiona J. Ruiz et al.

Summary: Persistent HPV infection is a known driver of cervical carcinogenesis, but the significance of HPV undetected (HPVU) cervical cancer has been debated. This study demonstrates that HPVU status can serve as a predictive biomarker of poor patient response to standard treatments and suggests personalized treatment plans for such patients. Palbociclib emerges as a promising alternative treatment for HPVU cervical cancer patients.

CANCERS (2021)

添加到收藏夹

Article Oncology

Low-dose CDK4/6 inhibitors induce presentation of pathway specific MHC ligands as potential targets for cancer immunotherapy

Angel Charles et al.

Summary: CDK4/6 inhibitors induce cell-cycle arrest and trigger T-cell immunity, possibly through changes in HLA ligands. In breast cancer cell lines, treatment with CDK4/6 inhibitors leads to upregulation of HLA and induction of new HLA ligands related to the G1/S phase transition, with high likelihood of being recognized by T cells. This suggests that inhibiting a specific cellular process can increase presentation of proteins targeted by immunotherapeutic agents.

ONCOIMMUNOLOGY (2021)

添加到收藏夹

Review Oncology

Human papillomavirus as a driver of head and neck cancers

Maria Elisa Sabatini et al.

BRITISH JOURNAL OF CANCER (2020)

添加到收藏夹

Article Oncology

Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial

Douglas Adkins et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness et al.

LANCET (2019)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E. W. Cohen et al.

LANCET (2019)

添加到收藏夹

Article Medicine, General & Internal

Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial

Maura L. Gillison et al.

LANCET (2019)

添加到收藏夹

Article Otorhinolaryngology

Prognostic factors in head and neck cancer: a 10-year retrospective analysis in a single-institution in Italy

G. Cadoni et al.

ACTA OTORHINOLARYNGOLOGICA ITALICA (2017)

添加到收藏夹

Article Oncology

EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer

Tim N. Beck et al.

MOLECULAR CANCER THERAPEUTICS (2016)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

R. L. Ferris et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Article Oncology

Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma

Loren Michel et al.

ORAL ONCOLOGY (2016)

添加到收藏夹

Article Multidisciplinary Sciences

Comprehensive genomic characterization of head and neck squamous cell carcinomas

Michael S. Lawrence et al.

NATURE (2015)

添加到收藏夹

Review Biotechnology & Applied Microbiology

The history and future of targeting cyclin-dependent kinases in cancer therapy

Uzma Asghar et al.

NATURE REVIEWS DRUG DISCOVERY (2015)

添加到收藏夹

Article Oncology

Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522

K. Kian Ang et al.

JOURNAL OF CLINICAL ONCOLOGY (2014)

添加到收藏夹

Article Oncology

Analysis of ECOG performance status in head and neck squamous cell carcinoma patients: association with sociodemographical and clinical factors, and overall survival

Gefter Thiago Batista Correa et al.

SUPPORTIVE CARE IN CANCER (2012)

添加到收藏夹

Article Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. A. Eisenhauer et al.

EUROPEAN JOURNAL OF CANCER (2009)

添加到收藏夹

Article Oncology

Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies

Jan. B. Vermorken et al.

CANCER (2008)

添加到收藏夹

Article Medicine, General & Internal

Platinum-based chemotherapy plus cetuximab in head and neck cancer

Jan B. Vermorken et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

添加到收藏夹

Article Oncology

Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines

LH Kalish et al.

CLINICAL CANCER RESEARCH (2004)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.